The report includes information on current developmental pipeline, complete with latest updates, and features on discontinued and dormant projects.

This report is built using data and information sourced from Global Industry s Direct’s proprietary databases, Firms ’s corporate website, SEC filings, investor presentations and featured press releases, both from industry player and market -specific third party sources, put together by Global Industry s Direct’s team.

Scope of the Research

- Technische Universitat Munchen - Brief industry player overview including business description, key information and facts, and its locations and subsidiaries.
- Review of current pipeline of Technische Universitat Munchen human therapeutic division.
- Detailed Analysis of pipeline therapeutics across various therapy areas.
- Coverage of current pipeline molecules in various stages of drug development, including the combination treatment modalities, across the globe.
- Product profiles for late stage and clinical stage products of Technische Universitat Munchen with complete description of the product’s developmental history, mechanism of action, therapeutic class, target and major milestones.
- Recent updates of the Technische Universitat Munchen’s pipeline in the last quarter.
- Key discontinued and dormant projects.
- Latest news and deals relating to the products.

Why Should You Get This Report?

- Evaluate Technische Universitat Munchen’s strategic position with total access to detailed information on its product pipeline.
- Assess the growth potential of Technische Universitat Munchen in its therapy areas of focus.
- Identify new drug targets and therapeutic classes in the Technische Universitat Munchen’s Research and Development portfolio and develop key strategic initiatives to reinforce pipeline in those areas.
- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps.
- Exploit collaboration and partnership opportunities with Technische Universitat Munchen.
- Avoid Intellectual Property Rights related issues.
- Explore the dormant and discontinued projects of Technische Universitat Munchen and identify potential opportunities in those areas.

Table Of Contents

Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 4
Technische Universitat Munchen Snapshot 5
Key Information 5
Key Facts 5
Technische Universitat Munchen - Research and Development Overview 6
Key Therapeutic Areas 6
Technische Universitat Munchen - Pipeline Review 9
Pipeline Products by Stage of Development 9
Pipeline Products - Monotherapy 10
Pipeline Products - Combination Treatment Modalities 11
Technische Universitat Munchen - Pipeline Products Glance 12
Technische Universitat Munchen - Late Stage Pipeline 12
Phase III Products/Combination Treatment Modalities 12
Technische Universitat Munchen Clinical Stage Pipeline Products 13
Phase II Products/Combination Treatment Modalities 13
Phase I Products/Combination Treatment Modalities 15
Technische Universitat Munchen - Drug Profiles 16
Letrozole 16
Product Description 16
Mechanism of Action 16
RandD Progress 16
cetuximab + fluorouracil + oxaliplatin 17
Product Description 17
Mechanism of Action 17
RandD Progress 18
Cetuximab + Oxaliplatin + Fluorouracil + Radiation Therapy 19
Product Description 19
Mechanism of Action 19
RandD Progress 19
Everolimus 21
Product Description 21
Mechanism of Action 21
RandD Progress 21
Gemcitabine + Oxaliplatin + Radiation Therapy 22
Product Description 22
Mechanism of Action 22
RandD Progress 22
Glivec 24
Product Description 24
Mechanism of Action 24
RandD Progress 24
Nilotinib + Everolimus 25
Product Description 25
Mechanism of Action 25
RandD Progress 25
Rituximab + Cyclophosphamide + Fludarabine Phosphate 26
Product Description 26
Mechanism of Action 26
RandD Progress 27
Rituximab for Transplantation (Technische Universitat Munchen) 28
Product Description 28
Mechanism of Action 28
RandD Progress 28
Trastuzumab + Anastrozole + Cyclophosphamide + Docetaxel + Epirubicin Hydrochloride + Goserelin + Tamoxifen Citrate + Radiation Therapy 29
Product Description 29
Mechanism of Action 30
RandD Progress 31
Vigil 32
Product Description 32
Mechanism of Action 32
RandD Progress 32
Imatinib + Capecitabine + Cisplatin 33
Product Description 33
Mechanism of Action 33
RandD Progress 33
Technische Universitat Munchen - Pipeline Analysis 35
Technische Universitat Munchen - Pipeline Products by Therapeutic Class 35
Technische Universitat Munchen Pipeline Products By Target 37
Technische Universitat Munchen - Pipeline Products by Route of Administration 39
Technische Universitat Munchen - Pipeline Products by Molecule Type 40
Technische Universitat Munchen - Locations And Subsidiaries 41
Head Office 41
Appendix 42
Methodology 42
Coverage 42
Secondary Research 42
Primary Research 42
Expert Panel Validation 43
Contact Us 43
Disclaimer 43List of Tables
Technische Universitat Munchen - Pipeline by Therapy Area and Indication, 2010 7
Technische Universitat Munchen - Pipeline by Stage of Development, 2010 9
Technische Universitat Munchen - Monotherapy Products in Pipeline, 2010 10
Technische Universitat Munchen - Combination Treatment Modalities in Pipeline, 2010 11
Technische Universitat Munchen - Phase III, 2010 12
Technische Universitat Munchen - Phase II, 2010 13
Technische Universitat Munchen - Phase I, 2010 15
Technische Universitat Munchen - Pipeline By Therapeutic Class, 2010 35
Technische Universitat Munchen - Pipeline By Target, 2010 37
Technische Universitat Munchen - Pipeline By Route of Administration, 2010 39
Technische Universitat Munchen - Pipeline By Molecule Type, 2010 40

List of Figures
Technische Universitat Munchen - Pipeline by Therapy Area and Indication, 2010 7
Technische Universitat Munchen - Pipeline by Stage of Development, 2010 9
Technische Universitat Munchen - Monotherapy Products in Pipeline, 2010 10
Technische Universitat Munchen - Combination Treatment Modalities in Pipeline, 2010 11
Technische Universitat Munchen - Pipeline By Therapeutic Class, 2010 35
Technische Universitat Munchen - Pipeline By Target, 2010 37
Technische Universitat Munchen - Pipeline By Route of Administration, 2010 39
Technische Universitat Munchen - Pipeline By Molecule Type, 2010 40

View This Report »

Find all the market research you need - instantly, in one place.

+1.2 Million Research Documents & Statistics +200,000 Trusted Public Sources 350 Industries With Global Coverage

24/7 Customer Support

Talk to Louis

+1 718 618 4302

Purchase Reports From Reputable Market Research Publishers

Diagnostics and Therapeutics for HIV: Global Markets

Diagnostics and Therapeutics for HIV: Global Markets

  • $ 6 650
  • Industry report
  • April 2014
  • by BCC Research

STUDY GOALS AND OBJECTIVES The aim of this report is to provide detailed market, technology and industry analyses to help readers quantify and qualify the market for products used in the treatment, testing ...

JAK and PI3K Signaling Pathway Markets

JAK and PI3K Signaling Pathway Markets

  • $ 6 650
  • Industry report
  • April 2014
  • by BCC Research

REPORT HIGHLIGHTS The global market for signal transduction therapies/inhibitors (JAK and PI3K) reached $173.5 million in 2012. This market is expected to grow to $464.5 million in 2013 and $2.2 billion ...

Therapeutics for Women%s Health: Technologies and Global Markets

Therapeutics for Women%s Health: Technologies and Global Markets

  • $ 6 650
  • Industry report
  • May 2014
  • by BCC Research

Use this report to: - Learn about the main women's health disorders and relevant disease prevalence population. - Identify the impact of demographic, economic, and other factors that will drive future ...


ReportLinker is an award-winning market research solution that finds, filters and organizes the latest industry data so you get all the market research you need - quickly, in one place.